Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
暂无分享,去创建一个
J. M. Porcel | S. Bielsa | M. Martinez-Alonso | José M Porcel | Silvia Bielsa | Paula Hernández | Montserrat Martínez-Alonso | Antonieta Salud | Paula Hernández | A. Salud | J. Porcel
[1] R. Hustinx,et al. 18F-FDG PET imaging in assessing exudative pleural effusions , 2006, Nuclear medicine communications.
[2] K. Azuma,et al. Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease , 2010, Japanese Journal of Radiology.
[3] Jin Woong. Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis , 2012 .
[4] R. Coleman,et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. , 2000, AJR. American journal of roentgenology.
[5] R. Louis,et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. , 2004, Chest.
[6] J. M. Porcel,et al. Pearls and myths in pleural fluid analysis , 2011, Respirology.
[7] K. Uematsu,et al. Clinical implications of 18 F-fluorodeoxyglucose positron emission tomography / computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma , 2011 .
[8] F. Fazio,et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[9] A. Alavi,et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. , 1998, Chest.
[10] U. Waheed,et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. , 2002, Chest.
[11] H. Biersack,et al. Impact of Dual-Time-Point F-18 FDG PET/CT in the Assessment of Pleural Effusion in Patients With Non-Small-Cell Lung Cancer , 2011, Clinical nuclear medicine.
[12] John O. Prior,et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis. , 2014, Lung Cancer.
[13] J. Monteil,et al. Assessment of 18F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases , 2004, European Respiratory Journal.
[14] A. Alavi,et al. Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease , 2009, Molecular Imaging and Biology.
[15] H. Schoellnast,et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. , 2004, Radiology.
[16] K. Bakır,et al. The role of FDG PET-CT in differential diagnosis of pleural pathologies. , 2012, Revista espanola de medicina nuclear e imagen molecular.
[17] U. Metser,et al. Differentiation Between Malignant and Benign Pleural Effusion in Patients With Extra-Pleural Primary Malignancies: Assessment With Positron Emission Tomography-Computed Tomography , 2005, Investigative radiology.
[18] H. Çiftçi,et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. , 2009, The Thoracic and cardiovascular surgeon.
[19] Susan Mallett,et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.
[20] M. Metintaş,et al. Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] Y. Nishiyama,et al. Dual time point FDG PET for evaluation of malignant pleural mesothelioma , 2009, Nuclear medicine communications.
[22] R. Hustinx,et al. Contribution of positron emission tomography in pleural disease. , 2010, Revue des maladies respiratoires.
[23] T. Nakano,et al. Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma. , 2012, Experimental and therapeutic medicine.
[24] J. M. Porcel,et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. , 2014, Archivos de bronconeumologia.
[25] Kyoungjune Pak,et al. Predictive Value of F-18 FDG PET/CT for Malignant Pleural Effusion in Non-Small Cell Lung Cancer Patients , 2011, Oncology Research and Treatment.
[26] S. Treves,et al. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] John O. Prior,et al. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. , 2014, Academic radiology.
[28] K. Uematsu,et al. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. , 2011, Oncology reports.
[29] A. Dowlati,et al. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. , 1997, Thorax.
[30] H. Groen,et al. PET for the evaluation of pleural thickening observed on CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] John O. Prior,et al. 18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer , 2012, Nuklearmedizin.
[32] T. Turkington,et al. A systematic review of the factors affecting accuracy of SUV measurements. , 2010, AJR. American journal of roentgenology.
[33] Xue-Ning Yang,et al. PET/CT鉴别肺癌中胸腔积液性质的临床价值 , 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[34] J. M. Porcel,et al. Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas , 2014 .
[35] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[36] C. Dooms,et al. Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience. , 2012, Radiology.